Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
NEW YORK, March 31, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Stemline Therapeutics, Inc. (NASDAQ:STML) securities (1) pursuant and/or traceable to Stemline’s secondary public offering on or about January 20, 2017; and/or (2) on the open market between January 6, 2017 and February 1, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/stemline-therapeutics. There is no cost or obligation to you.
The complaint alleges that during the class period the Company made materially false and/or misleading statements and/or failed to disclose that: (i) a patient had died in the BPDCN Trial from capillary leak syndrome immediately prior to the Company’s stock offering despite consistently stating that capillary leak syndrome was a potential side-effect of SL-401; and (ii) SL-401’s safety profile did not remain predictable and manageable over increasing treatment duration, drug exposure, and patient experience as represented by the Defendants.
If you suffered a loss in Stemline you have until April 4, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/stemline-therapeutics.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
